NO321139B1 - Farmasoytisk preparat egnet for subkutan, intramuskulaer eller intradermal administrering. - Google Patents
Farmasoytisk preparat egnet for subkutan, intramuskulaer eller intradermal administrering. Download PDFInfo
- Publication number
- NO321139B1 NO321139B1 NO19964081A NO964081A NO321139B1 NO 321139 B1 NO321139 B1 NO 321139B1 NO 19964081 A NO19964081 A NO 19964081A NO 964081 A NO964081 A NO 964081A NO 321139 B1 NO321139 B1 NO 321139B1
- Authority
- NO
- Norway
- Prior art keywords
- factor viii
- viii
- factor
- subcutaneous
- administration
- Prior art date
Links
- 238000007920 subcutaneous administration Methods 0.000 title claims abstract description 25
- 238000007918 intramuscular administration Methods 0.000 title claims abstract description 12
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 4
- 108010054218 Factor VIII Proteins 0.000 claims abstract description 80
- 102000001690 Factor VIII Human genes 0.000 claims abstract description 80
- 229960000301 factor viii Drugs 0.000 claims abstract description 68
- 239000000203 mixture Substances 0.000 claims abstract description 39
- 238000009472 formulation Methods 0.000 claims abstract description 37
- 229940105778 coagulation factor viii Drugs 0.000 claims abstract description 9
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 20
- 230000036470 plasma concentration Effects 0.000 claims description 18
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 13
- 229960002885 histidine Drugs 0.000 claims description 10
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 7
- 229920002674 hyaluronan Polymers 0.000 claims description 7
- 229960003160 hyaluronic acid Drugs 0.000 claims description 7
- 239000011780 sodium chloride Substances 0.000 claims description 7
- 108010010803 Gelatin Proteins 0.000 claims description 6
- -1 fatty acid ester Chemical class 0.000 claims description 6
- 229920000159 gelatin Polymers 0.000 claims description 6
- 239000008273 gelatin Substances 0.000 claims description 6
- 235000019322 gelatine Nutrition 0.000 claims description 6
- 235000011852 gelatine desserts Nutrition 0.000 claims description 6
- 102000008186 Collagen Human genes 0.000 claims description 5
- 108010035532 Collagen Proteins 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 4
- 239000000194 fatty acid Substances 0.000 claims description 4
- 229930195729 fatty acid Natural products 0.000 claims description 4
- 239000006259 organic additive Substances 0.000 claims description 4
- 239000004045 soybean oil emulsion Substances 0.000 claims description 4
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 2
- 230000004071 biological effect Effects 0.000 claims description 2
- 230000037058 blood plasma level Effects 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 229940050526 hydroxyethylstarch Drugs 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 210000004369 blood Anatomy 0.000 abstract description 19
- 239000008280 blood Substances 0.000 abstract description 19
- 239000000654 additive Substances 0.000 abstract description 14
- 239000003814 drug Substances 0.000 abstract description 13
- 201000003542 Factor VIII deficiency Diseases 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 102100022641 Coagulation factor IX Human genes 0.000 abstract description 6
- 230000000996 additive effect Effects 0.000 abstract description 6
- 238000012217 deletion Methods 0.000 abstract description 6
- 230000037430 deletion Effects 0.000 abstract description 6
- 208000009429 hemophilia B Diseases 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000012360 testing method Methods 0.000 abstract description 4
- 230000001965 increasing effect Effects 0.000 abstract description 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 2
- 108010076282 Factor IX Proteins 0.000 abstract 3
- 229940105774 coagulation factor ix Drugs 0.000 abstract 2
- 102100023804 Coagulation factor VII Human genes 0.000 abstract 1
- 108010023321 Factor VII Proteins 0.000 abstract 1
- 229960004222 factor ix Drugs 0.000 abstract 1
- 229940012413 factor vii Drugs 0.000 abstract 1
- 108010025139 recombinant factor VIII SQ Proteins 0.000 description 36
- 239000000243 solution Substances 0.000 description 17
- 210000002381 plasma Anatomy 0.000 description 15
- 208000009292 Hemophilia A Diseases 0.000 description 12
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 description 11
- 102100026735 Coagulation factor VIII Human genes 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 239000000839 emulsion Substances 0.000 description 10
- 108090000765 processed proteins & peptides Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 238000001990 intravenous administration Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000872 buffer Substances 0.000 description 7
- 239000006185 dispersion Substances 0.000 description 7
- 102000004196 processed proteins & peptides Human genes 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 6
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- 208000031220 Hemophilia Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 229960005069 calcium Drugs 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 239000001110 calcium chloride Substances 0.000 description 4
- 229910001628 calcium chloride Inorganic materials 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229910021645 metal ion Inorganic materials 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 229920001184 polypeptide Polymers 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- 150000002894 organic compounds Chemical class 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000001509 sodium citrate Substances 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 230000009885 systemic effect Effects 0.000 description 3
- DKWHHTWSTXZKDW-UHFFFAOYSA-N 1-[2-[2-[2-(2-butoxyethoxy)ethoxymethoxy]ethoxy]ethoxy]butane Chemical compound CCCCOCCOCCOCOCCOCCOCCCC DKWHHTWSTXZKDW-UHFFFAOYSA-N 0.000 description 2
- CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 241000282567 Macaca fascicularis Species 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 208000026552 Severe hemophilia A Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 229940019700 blood coagulation factors Drugs 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 239000004227 calcium gluconate Substances 0.000 description 2
- 235000013927 calcium gluconate Nutrition 0.000 description 2
- 229960004494 calcium gluconate Drugs 0.000 description 2
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 150000002337 glycosamines Chemical class 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229940127215 low-molecular weight heparin Drugs 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000013421 nuclear magnetic resonance imaging Methods 0.000 description 2
- 229960001412 pentobarbital Drugs 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000012266 salt solution Substances 0.000 description 2
- 235000012424 soybean oil Nutrition 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000008227 sterile water for injection Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- HNLXNOZHXNSSPN-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[4-(2,4,4-trimethylpentan-2-yl)phenoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCOCCOCCOCCOCCOCCOCCO)C=C1 HNLXNOZHXNSSPN-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000028782 Hereditary disease Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000028221 Mild hemophilia A Diseases 0.000 description 1
- 208000033375 Moderate hemophilia A Diseases 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 108010022394 Threonine synthase Proteins 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229960002283 calcium glubionate Drugs 0.000 description 1
- YPCRNBPOUVJVMU-LCGAVOCYSA-L calcium glubionate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.[O-]C(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YPCRNBPOUVJVMU-LCGAVOCYSA-L 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 229960002242 chlorocresol Drugs 0.000 description 1
- 239000008139 complexing agent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 208000011664 congenital factor XI deficiency Diseases 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000368 destabilizing effect Effects 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- GTXJHJOCVPTNTP-MLJFYOOPSA-N dimethyl-α-cyclodextrin Chemical compound COC[C@H]([C@H]([C@@H]([C@H]1OC)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O[C@H]3O[C@H](COC)[C@H]([C@@H]([C@H]3OC)O)O3)[C@H](O)[C@H]2OC)COC)O[C@@H]1O[C@H]1[C@H](O)[C@@H](OC)[C@@H]3O[C@@H]1COC GTXJHJOCVPTNTP-MLJFYOOPSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000008344 egg yolk phospholipid Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000007219 factor XI deficiency Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 229940089982 healon Drugs 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000002628 heparin derivative Substances 0.000 description 1
- 239000002634 heparin fragment Substances 0.000 description 1
- 102000057593 human F8 Human genes 0.000 description 1
- 229960000900 human factor viii Drugs 0.000 description 1
- 229940028435 intralipid Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 229960004452 methionine Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229920002114 octoxynol-9 Polymers 0.000 description 1
- 229940098514 octoxynol-9 Drugs 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9401105A SE9401105D0 (sv) | 1993-07-05 | 1994-03-31 | Formulation |
| SE9500036A SE9500036D0 (sv) | 1995-01-05 | 1995-01-05 | Formulation |
| PCT/SE1995/000348 WO1995026750A1 (en) | 1994-03-31 | 1995-03-31 | Pharmaceutical formulation for subcutaneous, intramuscular or intradermal administration of factor viii or factor ix |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964081D0 NO964081D0 (no) | 1996-09-27 |
| NO964081L NO964081L (no) | 1996-11-29 |
| NO321139B1 true NO321139B1 (no) | 2006-03-27 |
Family
ID=26662019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964081A NO321139B1 (no) | 1994-03-31 | 1996-09-27 | Farmasoytisk preparat egnet for subkutan, intramuskulaer eller intradermal administrering. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5925739A (de) |
| EP (1) | EP0772452B1 (de) |
| JP (1) | JP3939750B2 (de) |
| AT (1) | ATE222770T1 (de) |
| AU (1) | AU690666B2 (de) |
| BR (1) | BRPI9507227B8 (de) |
| CA (1) | CA2186126C (de) |
| DE (1) | DE69527966T2 (de) |
| DK (1) | DK0772452T3 (de) |
| ES (1) | ES2182899T3 (de) |
| FI (1) | FI118171B (de) |
| HU (1) | HU223314B1 (de) |
| IL (2) | IL113010A (de) |
| NO (1) | NO321139B1 (de) |
| NZ (1) | NZ283499A (de) |
| PL (1) | PL180282B1 (de) |
| PT (1) | PT772452E (de) |
| TW (1) | TW400234B (de) |
| WO (1) | WO1995026750A1 (de) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4430205A1 (de) * | 1994-08-26 | 1996-02-29 | Behringwerke Ag | Zusammensetzungen, die als Gegenmittel für Blut-Antikoagulanzien geeignet sind und deren Verwendung |
| SE9403915D0 (sv) * | 1994-11-14 | 1994-11-14 | Annelie Almstedt | Process A |
| SE9502285D0 (sv) * | 1995-06-22 | 1995-06-22 | Pharmacia Ab | Improvements related to injections |
| US5770700A (en) * | 1996-01-25 | 1998-06-23 | Genetics Institute, Inc. | Liquid factor IX formulations |
| WO1997039761A1 (en) * | 1996-04-19 | 1997-10-30 | Alpha Therapeutic Corporation | A process for viral inactivation of lyophilized blood proteins |
| US7560107B2 (en) | 1996-06-26 | 2009-07-14 | Emory University | Modified factor VIII |
| US5763401A (en) * | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
| US20050032690A1 (en) * | 1997-09-10 | 2005-02-10 | Rojkjaer Lisa Payne | Factor VII polypeptides for preventing formation of inhibitors in subjects with haemophilia |
| US6310183B1 (en) * | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
| US7786070B2 (en) * | 1997-09-10 | 2010-08-31 | Novo Nordisk Healthcare A/G | Subcutaneous administration of coagulation factor VII |
| US6586573B1 (en) | 1999-02-22 | 2003-07-01 | Baxter International Inc. | Albumin-free Factor VIII formulations |
| US8465468B1 (en) | 2000-06-29 | 2013-06-18 | Becton, Dickinson And Company | Intradermal delivery of substances |
| US20020156453A1 (en) * | 1999-10-14 | 2002-10-24 | Pettis Ronald J. | Method and device for reducing therapeutic dosage |
| JP4663837B2 (ja) * | 1999-12-24 | 2011-04-06 | 一般財団法人化学及血清療法研究所 | 第▲ｖｉｉｉ▼因子を主成分とする血小板減少に伴う出血疾患の予防・治療用医薬組成物 |
| US20020123093A1 (en) | 2000-04-06 | 2002-09-05 | Zannis Vassilis I. | Compounds and methods for lowering cholesterol levels without inducing hypertrigylceridemia |
| ES2449224T3 (es) | 2000-05-03 | 2014-03-18 | Novo Nordisk Health Care Ag | Administración subcutánea del Factor de coagulación VII |
| WO2004099231A2 (en) | 2003-04-09 | 2004-11-18 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
| KR20040065278A (ko) * | 2001-12-21 | 2004-07-21 | 노보 노르디스크 에이/에스 | 변경된 인자 ⅶ 폴리펩티드의 액체 조성물 |
| DE60232017D1 (de) | 2001-12-21 | 2009-05-28 | Novo Nordisk Healthcare Ag | Flüssige zusammensetzung aus faktor vii polypeptiden |
| US20040009918A1 (en) * | 2002-05-03 | 2004-01-15 | Hanne Nedergaard | Stabilised solid compositions of modified factor VII |
| JP4648002B2 (ja) | 2002-06-21 | 2011-03-09 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | 第ｖｉｉ因子ポリペプチドの安定化された固体組成物 |
| RU2005132164A (ru) * | 2003-03-18 | 2006-06-10 | Ново Нордиск Хелт Кэр Аг (Ch) | Жидкие, водные фармацевтические композиции полипептидов фактора vii |
| US7897734B2 (en) * | 2003-03-26 | 2011-03-01 | Novo Nordisk Healthcare Ag | Method for the production of proteins |
| US7977460B2 (en) * | 2003-05-19 | 2011-07-12 | National Institute For Biological Standards And Control | Compositions comprising coagulation factors IXA and VIII for the treatment of haemophilia A or B |
| EP1628677B1 (de) * | 2003-05-23 | 2010-01-13 | Novo Nordisk Health Care AG | Stabilisierung von proteinen in lösung |
| ATE547114T1 (de) * | 2003-06-25 | 2012-03-15 | Novo Nordisk Healthcare Ag | Flüssige zusammensetzungen von factor vii polypeptiden |
| ATE446768T1 (de) * | 2003-07-01 | 2009-11-15 | Novo Nordisk Healthcare Ag | Flüssige wässrige pharmazeutische zusammnesetzung von factor vii polypeptiden |
| WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
| AU2004264282B2 (en) * | 2003-08-14 | 2010-10-14 | Novo Nordisk Health Care Ag | Liquid, aqueous pharmaceutical composition of Factor VII polypeptides |
| ES2229931B1 (es) * | 2003-10-03 | 2006-01-16 | Grifols, S.A. | Composicion liquida bilogicamente estable de fviii, de fvw o del complejo fviii/fvw humanos. |
| US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
| PT2298287T (pt) * | 2003-12-19 | 2018-07-23 | Novo Nordisk Healthcare Ag | Composições estabilizadas de polipéptidos de fator vii |
| FR2868704B1 (fr) * | 2004-04-07 | 2007-09-14 | Ethypharm Sa | Utilisation de lipides pour ameliorer la biodisponibilite de principes actifs proteiques en formulations injectables sous cutanees ou intra-musculaires |
| ES2449044T3 (es) * | 2004-05-03 | 2014-03-18 | Emory University | Procedimiento de administración de fVIII sin dominio B porcino |
| WO2006010143A2 (en) | 2004-07-13 | 2006-01-26 | Neose Technologies, Inc. | Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1] |
| US20080176790A1 (en) | 2004-10-29 | 2008-07-24 | Defrees Shawn | Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf) |
| HUE033776T2 (en) * | 2004-11-12 | 2018-01-29 | Bayer Healthcare Llc | FVIII site-specific modification |
| MX2007008229A (es) | 2005-01-10 | 2007-09-11 | Neose Technologies Inc | Factor estimulador de colonias de granulocitos glicopegilado. |
| WO2006103298A2 (en) * | 2005-04-01 | 2006-10-05 | Novo Nordisk Health Care Ag | Blood coagulation fviii analogues |
| US9187546B2 (en) | 2005-04-08 | 2015-11-17 | Novo Nordisk A/S | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
| US20070105755A1 (en) * | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
| WO2007056191A2 (en) | 2005-11-03 | 2007-05-18 | Neose Technologies, Inc. | Nucleotide sugar purification using membranes |
| EP2049144B8 (de) | 2006-07-21 | 2015-02-18 | ratiopharm GmbH | Glycosylierung von peptiden über o-verbundene glycosylierungssequenzen |
| EP2054521A4 (de) | 2006-10-03 | 2012-12-19 | Novo Nordisk As | Verfahren zur reinigung von polypeptid-konjugate |
| EP2099475B1 (de) * | 2007-01-03 | 2016-08-24 | Novo Nordisk Health Care AG | Subkutane verabreichung von polypeptiden in zusammenhang mit dem gerinnungsfaktor viia |
| JP2010523582A (ja) | 2007-04-03 | 2010-07-15 | バイオジェネリクス アクチェンゲゼルシャフト | グリコｐｅｇ化ｇ−ｃｓｆを用いた治療方法 |
| JP5401446B2 (ja) | 2007-04-26 | 2014-01-29 | バイエル ヘルスケア エルエルシー | 凍結貯蔵を目的とした、組み換えタンパク質溶液の安定化 |
| MX2009013259A (es) | 2007-06-12 | 2010-01-25 | Novo Nordisk As | Proceso mejorado para la produccion de azucares de nucleotidos. |
| EP2486936A1 (de) | 2007-06-13 | 2012-08-15 | CSL Behring GmbH | Eine Zusammensetzung enthaltend VWF und FVIII zur Vervendung in der Behandlung von Blutungsstörungen |
| CN103497247A (zh) * | 2008-02-27 | 2014-01-08 | 诺沃—诺迪斯克有限公司 | 缀合的因子viii分子 |
| CN102202684A (zh) * | 2008-11-03 | 2011-09-28 | 拜耳医药保健有限公司 | 用于治疗血友病的方法 |
| AU2009313325B2 (en) | 2008-11-07 | 2014-05-01 | Takeda Pharmaceutical Company Limited | Factor VIII formulations |
| EP2467166A2 (de) * | 2009-08-20 | 2012-06-27 | CSL Behring GmbH | Albuminfusionierte koagulationsfaktoren zur nicht-intravenösen verabreichung bei der behandlung und prophylaktischen behandlung von blutungsstörungen |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| KR101948337B1 (ko) | 2010-11-05 | 2019-02-14 | 박스알타 인코퍼레이티드 | 증가된 특이 활성도를 갖는 항혈우병 인자 ｖｉｉｉ의 신규 변이체 |
| JP6029674B2 (ja) | 2011-10-18 | 2016-11-24 | ツェー・エス・エル・ベーリング・ゲー・エム・ベー・ハー | 第ｖｉｉｉ因子のバイオアベイラビリティを改善するための、硫酸化グリコサミノグリカン及びヒアルロニダーゼの組み合わせ使用 |
| WO2013057167A1 (en) | 2011-10-18 | 2013-04-25 | Csl Behring Gmbh | Use of sulfated glycosaminoglycans for improving the bioavailability of factor viii |
| EA033469B1 (ru) * | 2012-04-16 | 2019-10-31 | Cantab Biopharmaceuticals Patents Ltd | Подкожное введение конъюгатов факторов крови с полиэтиленгликолем |
| EP2841451A1 (de) | 2012-04-24 | 2015-03-04 | Novo Nordisk A/S | Verbindungen zur behandlung von hämophilie |
| AU2013203062C1 (en) | 2013-03-15 | 2018-06-28 | Takeda Pharmaceutical Company Limited | Subcutaneous administration of adamts13 |
| RS60003B1 (sr) * | 2013-03-15 | 2020-04-30 | Bioverativ Therapeutics Inc | Formulacije polipeptida faktora viii |
| DK2796145T3 (da) | 2013-04-22 | 2018-01-29 | Csl Ltd | Et kovalent kompleks af von Willebrand-faktor og faktor VIII linket af en disulfidbro |
| KR20170010895A (ko) | 2014-06-06 | 2017-02-01 | 옥타파마 아게 | 인자 ⅷ 및 폰 빌레브란트 인자 펩티드를 포함하는 조제 |
| GB201417589D0 (en) * | 2014-10-06 | 2014-11-19 | Cantab Biopharmaceuticals Patents Ltd | Pharmaceutical Formulations |
| EP3733199A1 (de) | 2016-07-08 | 2020-11-04 | CSL Behring Lengnau AG | Subkutane verabreichung des langzeitfaktors ix beim menschen |
| CA3043397A1 (en) | 2016-11-11 | 2018-05-17 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| CN114929261A (zh) | 2020-02-17 | 2022-08-19 | 生物测试股份公司 | 凝血因子viii的皮下施用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56127308A (en) * | 1980-03-11 | 1981-10-06 | Green Cross Corp:The | Blood-coagulation factor 8 pharmaceutical |
| FI86885C (fi) * | 1984-04-20 | 1992-10-26 | Genentech Inc | Foerfarande foer framstaellning av human rekombinantfaktor viii och nukleinsyrasekvenser och vektorer anvaend daertill |
| US4965199A (en) * | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| SE8501050D0 (sv) * | 1985-03-05 | 1985-03-05 | Kabivitrum Ab | Biologically active fragments of human antihemophilic factor and method for preparation thereof |
| US5576194A (en) * | 1986-07-11 | 1996-11-19 | Bayer Corporation | Recombinant protein production |
| SE465222C5 (sv) * | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| DE4001451A1 (de) * | 1990-01-19 | 1991-08-01 | Octapharma Ag | Stabile injizierbare loesungen von faktor viii und faktor ix |
| NL9001681A (nl) * | 1990-07-24 | 1992-02-17 | Rijksuniversiteit | Transmucosale geneesmiddelpreparaten en transmucosale toediening. |
| DE69227607T2 (de) * | 1991-07-10 | 1999-04-15 | Takeda Chemical Industries, Ltd., Osaka | Arzneimittel auf Basis von Hyaluronsäure |
| GB9122609D0 (en) * | 1991-10-24 | 1991-12-04 | Brownlee George G | Improvements relating to the treatment of haemophilia |
| WO1993022336A1 (en) * | 1992-04-30 | 1993-11-11 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor viii complex |
| GB9211538D0 (en) * | 1992-06-01 | 1992-07-15 | Blake David R | Antiinflammatory agent |
| CZ290342B6 (cs) * | 1992-10-02 | 2002-07-17 | Genetics Institute Inc. | Kompozice stabilní při skladování, obsahující koagulační faktor VIII a neiontovou povrchově aktivní látku a způsob její výroby |
| SE9301581D0 (sv) * | 1993-05-07 | 1993-05-07 | Kabi Pharmacia Ab | Protein formulation |
| SE504074C2 (sv) * | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
-
1995
- 1995-03-16 IL IL11301099A patent/IL113010A/xx not_active IP Right Cessation
- 1995-03-16 IL IL11301095A patent/IL113010A0/xx unknown
- 1995-03-17 TW TW084102570A patent/TW400234B/zh not_active IP Right Cessation
- 1995-03-31 NZ NZ283499A patent/NZ283499A/xx not_active IP Right Cessation
- 1995-03-31 DK DK95914669T patent/DK0772452T3/da active
- 1995-03-31 ES ES95914669T patent/ES2182899T3/es not_active Expired - Lifetime
- 1995-03-31 JP JP52561695A patent/JP3939750B2/ja not_active Expired - Fee Related
- 1995-03-31 CA CA002186126A patent/CA2186126C/en not_active Expired - Fee Related
- 1995-03-31 PL PL95316618A patent/PL180282B1/pl not_active IP Right Cessation
- 1995-03-31 HU HU9602693A patent/HU223314B1/hu not_active IP Right Cessation
- 1995-03-31 AU AU21560/95A patent/AU690666B2/en not_active Ceased
- 1995-03-31 BR BRPI9507227A patent/BRPI9507227B8/pt not_active IP Right Cessation
- 1995-03-31 AT AT95914669T patent/ATE222770T1/de active
- 1995-03-31 DE DE69527966T patent/DE69527966T2/de not_active Expired - Lifetime
- 1995-03-31 US US08/716,140 patent/US5925739A/en not_active Expired - Lifetime
- 1995-03-31 WO PCT/SE1995/000348 patent/WO1995026750A1/en active IP Right Grant
- 1995-03-31 EP EP95914669A patent/EP0772452B1/de not_active Expired - Lifetime
- 1995-03-31 PT PT95914669T patent/PT772452E/pt unknown
-
1996
- 1996-09-27 FI FI963871A patent/FI118171B/fi not_active IP Right Cessation
- 1996-09-27 NO NO19964081A patent/NO321139B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| ES2182899T3 (es) | 2003-03-16 |
| IL113010A0 (en) | 1995-10-31 |
| PL180282B1 (pl) | 2001-01-31 |
| NO964081D0 (no) | 1996-09-27 |
| EP0772452B1 (de) | 2002-08-28 |
| IL113010A (en) | 1999-10-28 |
| US5925739A (en) | 1999-07-20 |
| JPH10501522A (ja) | 1998-02-10 |
| AU690666B2 (en) | 1998-04-30 |
| HU9602693D0 (en) | 1996-11-28 |
| MX9604455A (es) | 1997-07-31 |
| FI963871A0 (fi) | 1996-09-27 |
| EP0772452A1 (de) | 1997-05-14 |
| FI963871A (fi) | 1996-09-27 |
| FI118171B (fi) | 2007-08-15 |
| HUT74918A (en) | 1997-03-28 |
| NZ283499A (en) | 1997-08-22 |
| WO1995026750A1 (en) | 1995-10-12 |
| PT772452E (pt) | 2003-01-31 |
| ATE222770T1 (de) | 2002-09-15 |
| DE69527966T2 (de) | 2003-05-28 |
| HU223314B1 (hu) | 2004-05-28 |
| PL316618A1 (en) | 1997-01-20 |
| AU2156095A (en) | 1995-10-23 |
| JP3939750B2 (ja) | 2007-07-04 |
| DK0772452T3 (da) | 2003-01-06 |
| BR9507227A (pt) | 1997-09-09 |
| DE69527966D1 (de) | 2002-10-02 |
| TW400234B (en) | 2000-08-01 |
| CA2186126C (en) | 2007-11-20 |
| NO964081L (no) | 1996-11-29 |
| BRPI9507227B8 (pt) | 2015-12-08 |
| CA2186126A1 (en) | 1995-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO321139B1 (no) | Farmasoytisk preparat egnet for subkutan, intramuskulaer eller intradermal administrering. | |
| EP0710114B1 (de) | Eine formulierung des gerinnungsfaktors viii | |
| AU2012326080A1 (en) | Etanercept formulations stabilized with meglumine | |
| WO1995016460A1 (fr) | Dispositif a semi-conducteur | |
| JPH0358998A (ja) | 高純度タンパク質の安定化 | |
| NO324064B1 (no) | Farmasoytisk preparat omfattende vWF-propeptid samt fremgangsmate for fremstilling og anvendelse derav | |
| MX2013014894A (es) | Formulaciones liofilizadas del factor de crecimiento de fibroblastos 18. | |
| CA2130762C (en) | Treatment of disease and conditions associated with macrophage infiltration | |
| JP3822383B2 (ja) | 可溶性トロンボモジュリン含有組成物 | |
| JPH03218399A (ja) | 尿由来の抗血液疑固物質、その製法およびそれを含有する医薬組成物 | |
| KR100373882B1 (ko) | 인자ⅷ의피하,근내또는피내투여용약제학적제형 | |
| MXPA96004455A (en) | Pharmaceutical formulation for administracionsubcutanea, intramuscular or intradermica of factorviii or factor | |
| JP2002060345A (ja) | 血液凝固能異常に係わる疾患の予防・治療剤 | |
| AU2772092A (en) | Treatment of haemophilia | |
| EP0763360A1 (de) | Mittel gegen lebererkrankungen | |
| JPH0565231A (ja) | エリスロポエチンの持続性製剤 | |
| WO2023017020A1 (en) | Method for producing human plasma-derived factor viii / von willebrand factor and composition obtained | |
| JPH083065A (ja) | 肝臓障害に対する治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |